Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03286218 · ClinicalTrials.gov registry record · Phase 1
A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug Users
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
NCT03286218 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 96 participants.
The verdict
NCT03286218, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the abuse potential of study drug lasmiditan. Lasmiditan will be compared to a marketed benzodiazepine, alprazolam (positive control), as well as to placebo (dummy substance that looks like lasmiditan or alprazolam without any active drug) to determine the potential for drug abuse. The dosages will be in tablet form and will be taken orally (by mouth). This study will last about 55 days, including screening. Screening will occur within 28 days prior to qualification phase.
Interventions
- DRUG Placebo
- DRUG Alprazolam
- DRUG Lasmiditan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2017-09-15 |
| Est. Completion | 2017-11-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03286218
The ClinicalTrials.gov registry entry for NCT03286218 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03286218 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03286218 about?
NCT03286218 is a clinical study titled "A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug Users". The purpose of this study is to assess the abuse potential of study drug lasmiditan. Lasmiditan will be compared to a marketed benzodiazepine, alprazolam (positive control), as well as to placebo (dummy substance that looks like lasmiditan or alprazolam without any active drug) to determine the pot...
What is the current status of trial NCT03286218?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2017-09-15. Estimated completion is 2017-11-20.
What interventions are being tested in trial NCT03286218?
The interventions under investigation include: Placebo (DRUG), Alprazolam (DRUG), Lasmiditan (DRUG).
Who is sponsoring clinical trial NCT03286218?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.